Diasorin announces the launch of new Primer Pairs for use in molecular testing: Legionella species, Chlamydophila pneumoniae and Mycoplasma pneumoniae.

December 21, 2018 - Saluggia (VC) - Diasorin (FTSE MIB: DIA) announced today to have launched three new Primer Pairs for use in molecular testing as part of laboratory developed tests (LDTs).

The specific targets, developed by Diasorin Molecular LLC in Cypress, California are Legionella species, Chlamydophila pneumoniae and Mycoplasma pneumoniae, all of which may infect the lungs.

Legionella, which causes “Legionnaire’s Disease”, is the most serious of the three, and about one in ten people who get sick with it will die due to complications.

M. pneumoniae often causes “Walking pneumonia,” although it can progress to full pneumonia. There are an estimated 300,000 cases of C. pneumoniae each year in the U.S., with a range of severity. Both C. pneumoniae and M. pneumoniae are spread by human contact, whereas Legionella is spread by breathing droplets of contaminated water.

“Molecular tests that make use of primer pairs, such as the new ASRs (Analyte Specific Reagents), may be useful in detecting these bacteria that are difficult to culture.” said Michelle Tabb, Chief Scientific Officer at Diasorin Molecular LLC. “With a growing menu of more than 50 primer pairs, ASR development and manufacture remain one of our main growth drivers.”

About Diasorin

Headquartered in Italy and listed in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, Diasorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify Diasorin Group as the “Diagnostic Specialist.”

For additional information, please contact:

Riccardo Fava  
Investor Relations & Corporate Communication Senior Director  
Tel: +39.0161.487988  
riccardo.fava@diasorin.it

Ines Di Terlizzi  
Investor Relator  
Tel: +39.0161.487567  
inestiterlizzi@diasorin.it